We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Senate Amendment Bad for Drug Safety, PhRMA Says

Senate Amendment Bad for Drug Safety, PhRMA Says

July 25, 2006

The Senate’s approval of an amendment allowing for the importation of drugs from Canada undermines both government border control and the safety and efficacy of the U.S. drug supply, an industry group says.

To View This Article:

Login

Register
Forgot your password?

Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $10.00

Upcoming Events

  • 28Sep

    The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

  • 28Sep

    Calculating Sample Size to Satisfy FDA Expectations

  • 11Oct

    GMP Quality Management vSummit 2023: Where Quality Meets Risk

  • 16Oct

    MAGI@home Clinical Research Conference 2023

  • 26Oct

    FDA in 2024: What to Expect in an Election Year

  • 08Nov

    18th Annual FDA Inspections vSummit

Featured Products

  • FDA, FTC and DOJ Enforcement of Medical Device Regulations

    FDA, FTC and DOJ Enforcement of Medical Device Regulations

  • Using Real-World Evidence in Drug and Device Submissions

    Using Real-World Evidence in Drug and Device Submissions

Featured Stories

  • Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

  • Artificial Womb Technology Not Yet Ready for Human Trials Adcomm Says

  • Top Concern for CBER is Marketing of Unapproved Biologics, Says FDA Official

  • FDA Deems Medline Industries’ Saline Solution Vial Recall as Class 1

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing